In an editorial, one expert said the choice of DOAC in VTE is “no longer a toss-up,” with apixaban the clear winner.
Apixaban conferred lower bleeding risk during a 3-month period compared with rivaroxaban in patients with acute venous thromboembolism, researchers reported.Despite higher medication adherence to ...
Significantly lower risk for clinically relevant bleeding seen with apixaban than rivaroxaban during three-month trial period.
The first clinical trial to compare two commonly used drugs head-to-head for venous thrombosis treatment has found a clear winner: while both drugs work well to prevent recurrent blood clots, apixaban ...
March 13 (Reuters) - A trial directly comparing Eliquis and Xarelto - two commonly used blood-thinning drugs from the same ...
The FDA approved the first generics of the direct oral anticoagulant rivaroxaban, the agency announced on Tuesday. Rivaroxaban 2.5 mg tablets from Lupin and Taro are now considered therapeutic ...
In patients with venous thromboembolism (VTE) who are candidates for oral anticoagulation, apixaban results in fewer hospitalizations for recurrence and less major bleeding than rivaroxaban or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results